Recruiting PHASE3 INTERVENTIONAL 3-arm NCT07028827

Atropine Eyedrops for Myopia Progression in Children and Adolescents (MODERATO STUDY) (MODERATO)

A Phase III, Randomized, Double-blind, Multiple Doses, Placebo-controlled, Parallel-group Adaptive Study to Evaluate the Efficacy and Safety of Atropine for the Treatment of Myopia Progression in Children and Adolescents (MODERATO Study)

Sponsor: Consorzio per Valutazioni Biologiche e Farmacologiche

Conditions Myopia

Interventions 0.025% atropine eye drops 0.05% atropine eye drops placebo eye drops

Updated 4 times since 2025 Last updated: Feb 10, 2026 Started: Sep 1, 2025 Primary completion: Dec 31, 2027 Completion: Dec 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Myopia, this trial is actively recruiting participants. The trial is conducted by Consorzio per Valutazioni Biologiche e Farmacologiche and has accumulated 4 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE3
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Sep 2025 — Jan 2026 [monthly]

Not Yet Recruiting PHASE3
Jul 2025 — Sep 2025 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Consorzio per Valutazioni Biologiche e Farmacologiche
Euromed Pharma Services SRL
Ocus Innovation Ireland Limited

Data source: Ocus Innovation Ireland Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Bari, Italy , Belfast, United Kingdom , Birmingham, United Kingdom , Cadiz, Spain , London, United Kingdom , Madrid, Spain , Milan, Italy , Padua, Italy , Tirana, Albania and 1 more location